Common Medications Linked to Kidney Stones
Author Information
Author(s): Bao Erhao, Yang Yang, Jiang Binglei, Wang Ben, Liu Ying, Yang Lin, Xia Long, Zhu Pingyu
Primary Institution: Affiliated Hospital of North Sichuan Medical College
Hypothesis
This research project aimed to identify and analyze the top 30 drugs most commonly associated with kidney stone formation using data from the U.S. Food and Drug Administration’s Adverse Event Reporting System (FAERS) database.
Conclusion
The study identified specific medications that are associated with an increased risk of kidney stones, which can help in managing and reducing this health issue.
Supporting Evidence
- Atazanavir was found to have a very high risk of developing nephrolithiasis with an ROR of 46.35.
- Topamax was associated with a 2-4 times higher risk of kidney stones compared to the general population.
- Proton pump inhibitors like Prevacid were linked to increased incidence and recurrence rates of kidney stones.
Takeaway
Some medicines can make people more likely to get kidney stones, and knowing which ones can help doctors keep patients safe.
Methodology
The study used the FDA Adverse Event Reporting System (FAERS) database to extract data from 2010 to 2024, focusing on drug-induced kidney stones and employing disproportionality analyses to calculate Reporting Odds Ratios (ROR) and Proportional Reporting Ratios (PRR).
Potential Biases
The FAERS database may favor reporting of more severe adverse events, potentially leading to an underrepresentation of less severe cases.
Limitations
The study is limited by biases in the FAERS database, including underreporting and a lack of severity ratings for adverse reactions.
Participant Demographics
{"gender_ratio":"1:1.34 (male to female)","age_distribution":"Mainly concentrated in the age group of 18–65 years (42.6%)"}
Statistical Information
Confidence Interval
95% CI for ROR values ranged from 43 to 50 for the most common drugs.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website